Suppr超能文献

印度人群中静脉注射地塞米松治疗特发性视神经炎后的视力预后:临床病例系列

Visual outcome after intravenous dexamethasone therapy for idiopathic optic neuritis in an Indian population: a clinical case series.

作者信息

Sethi Harinder Singh, Menon Vimla, Sharma Pradeep, Khokhar Sudarshan, Tandon Radhika

机构信息

Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

出版信息

Indian J Ophthalmol. 2006 Sep;54(3):177-83. doi: 10.4103/0301-4738.27069.

Abstract

PURPOSE

To evaluate the clinical profile, response to dexamethasone treatment and visual function outcome in Indian patients with acute optic neuritis.

MATERIALS AND METHODS

We conducted an observational study of patients with acute optic neuritis who were treated with intravenous dexamethasone (100 mg in 250 ml of 5% dextrose over 1-2 hours daily, for three consecutive days) and had completed at least two years of follow-up. Parameters assessed included visual acuity, contrast sensitivity, color vision, visual fields, relative afferent pupillary defect (RAPD) and visually evoked potentials. Out of 40 patients studied, 26 patients (33 eyes) had all visual function parameters assessed. Twenty three patients (28 eyes) had completed two years of follow-up and were included for statistical analysis.

RESULTS

Improvement in visual acuity was statistically significant for distance after 24 hours of the first dose (P = < 0.001) and for near vision after 24 hours of the second dose (P = 0.006); improvement in color and contrast sensitivity was statistically significant 24 hours after the third dose (P = < 0.001 for color vision and P = 0.013 for contrast sensitivity). Significant improvement in RAPD and visual fields were seen by 1 month (P = 0.005). Recurrence was seen in 4 eyes of 4 patients. No serious side effects were observed. At two years, 82.14% (23 out of 28) eyes had visual acuity > 20/40.

CONCLUSION

Treatment with intravenous pulsed dexamethasone led to rapid recovery of vision in acute optic neuritis, without any serious side effects.

摘要

目的

评估印度急性视神经炎患者的临床特征、对地塞米松治疗的反应及视觉功能预后。

材料与方法

我们对接受静脉注射地塞米松治疗(每日1 - 2小时内将100毫克地塞米松溶于250毫升5%葡萄糖溶液中,连续三天)且完成至少两年随访的急性视神经炎患者进行了一项观察性研究。评估的参数包括视力、对比敏感度、色觉、视野、相对传入性瞳孔障碍(RAPD)和视觉诱发电位。在研究的40例患者中,26例患者(33只眼)评估了所有视觉功能参数。23例患者(28只眼)完成了两年随访并纳入统计分析。

结果

首剂后24小时远距离视力改善具有统计学意义(P = < 0.001),第二剂后24小时近距离视力改善具有统计学意义(P = 0.006);第三剂后24小时色觉和对比敏感度改善具有统计学意义(色觉P = < 0.001,对比敏感度P = 0.013)。1个月时RAPD和视野有显著改善(P = 0.005)。4例患者的4只眼出现复发。未观察到严重副作用。两年时,82.14%(28只眼中的23只)眼视力> 20/40。

结论

静脉注射脉冲式地塞米松治疗可使急性视神经炎患者视力快速恢复,且无任何严重副作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验